WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2018.
“We are proceeding with the enrollment of patients in five late-stage clinical efficacy trials with three innovative product candidates that address significant unmet needs in large CNS markets,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Our attention is focused on the careful execution of these trials, including patient selection, clinical site monitoring and close interaction with investigators.
“During the past quarter, The Journal of Clinical Psychiatry published online Phase 2b trial results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101),” said Dr. Luthringer. “Cognitive improvements were observed to correlate with previously reported improvements in negative symptoms, an important finding given that cognitive impairment, like negative symptoms, is a primary driver of functional disability in schizophrenia and a significant unmet medical need for patients with this disease.”
The ongoing trials with the Company’s clinical-stage product candidates include the following:
- Roluperidone: Phase 3 trial to treat negative symptoms in patients diagnosed with schizophrenia (monotherapy); top line results from the 12-week double blind phase of this trial are expected in the first half of 2019.
- MIN-117: Phase 2b trial to treat patients with major depressive disorder who also have symptoms of anxiety (monotherapy); top-line results are expected in the first half of 2019.
- Seltorexant (MIN-202): two Phase 2b trials to treat patients with major depressive disorder (adjunctive therapy); results expected in 2019.
- Seltorexant: one Phase 2b trial to treat patients with insomnia disorder (monotherapy); results expected in 2019.
Second Quarter 2018 Financial Results
- Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of June 30, 2018 were approximately $108.6 million, compared to $133.3 million as of December 31, 2017.
- R&D Expenses: Research and development (R&D) expenses were $9.1 million in the second quarter of 2018, compared to $7.1 million in the second quarter of 2017, an increase of $2.0 million. The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the Amendment to our Co-Development and License Agreement with Janssen. We expect R&D expenses to increase during 2018 as we increase patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
For the six months ended June 30, 2018, R&D expenses were $17.5 million, compared to $14.8 million for the six months ended June 30, 2017, an increase of $2.7 million. The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the Amendment to our Co-Development and License Agreement with Janssen. We expect R&D expenses to increase during 2018 as we increase patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
- G&A Expenses: General and administrative (G&A) expenses were $3.9 million in the second quarter of 2018, compared to $2.6 million in the second quarter of 2017, an increase of approximately $1.3 million. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support our pre-commercial activities. We expect G&A expenses to increase during 2018 as we begin to invest in the infrastructure necessary to support the Company’s growth.
For the six months ended June 30, 2018, G&A expenses were $8.2 million, compared to $5.5 million for the same period in 2017, an increase of approximately $2.7 million. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support our pre-commercial activities. We expect G&A expenses to increase during 2018 as we begin to invest in the infrastructure necessary to support the Company’s growth.
- Net Loss: Net loss was $12.5 million for the second quarter of 2018, or a loss per share of $0.32 (basic and diluted), as compared to a net loss of $9.8 million, or a loss per share of $0.27 (basic and diluted) for the second quarter of 2017. Net loss was $24.9 million for the first six months of 2018, or a loss per share of $0.64 (basic and diluted), as compared to a net loss of $20.4 million, or a loss per share of $0.57 (basic and diluted) for the first six months of 2017.
Conference Call Information:
Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities. To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 1686118.
The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
| CONDENSED CONSOLIDATED BALANCE SHEET DATA | ||||||
| (Unaudited) | ||||||
| June 30, | December 31, | |||||
| 2018 | 2017 | |||||
| (in thousands) | ||||||
| ASSETS | ||||||
| Current Assets: | ||||||
| Cash and cash equivalents | $ | 68,689 | $ | 26,052 | ||
| Marketable securities | 39,799 | 102,109 | ||||
| Restricted cash | 100 | 80 | ||||
| Prepaid expenses and other current assets | 3,229 | 1,299 | ||||
| Total current assets | 111,817 | 129,540 | ||||
| Marketable securities - noncurrent | - | 5,023 | ||||
| Equipment, net | 42 | 51 | ||||
| Other noncurrent assets | 15 | 15 | ||||
| In-process research and development | 34,200 | 34,200 | ||||
| Goodwill | 14,869 | 14,869 | ||||
| Total Assets | $ | 160,943 | $ | 183,698 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities: | ||||||
| Notes payable | $ | 1,397 | $ | 3,962 | ||
| Accounts payable | 1,310 | 1,436 | ||||
| Accrued expenses and other current liabilities | 2,311 | 1,439 | ||||
| Total current liabilities | 5,018 | 6,837 | ||||
| Long-Term Liabilities: | ||||||
| Deferred taxes | 4,057 | 4,057 | ||||
| Deferred revenue | 41,176 | 41,176 | ||||
| Other noncurrent liabilities | 31 | 30 | ||||
| Total liabilities | 50,282 | 52,100 | ||||
| Stockholders' Equity: | ||||||
| Common stock | 4 | 4 | ||||
| Additional paid-in capital | 299,986 | 295,975 | ||||
| Accumulated deficit | (189,329 | ) | (164,381 | ) | ||
| Total stockholders' equity | 110,661 | 131,598 | ||||
| Total Liabilities and Stockholders' Equity | $ | 160,943 | $ | 183,698 | ||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | |||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||
| Revenues | $ | - | $ | - | $ | - | $ | - | ||||||
| Operating expenses: | ||||||||||||||
| Research and development | 9,062 | 7,144 | 17,512 | 14,758 | ||||||||||
| General and administrative | 3,873 | 2,601 | 8,167 | 5,472 | ||||||||||
| Total operating expenses | 12,935 | 9,745 | 25,679 | 20,230 | ||||||||||
| Foreign exchange losses | 29 | (20 | ) | 11 | (37 | ) | ||||||||
| Investment income | 412 | 156 | 826 | 214 | ||||||||||
| Interest expense | (36 | ) | (170 | ) | (106 | ) | (372 | ) | ||||||
| Net income (loss) | $ | (12,530 | ) | $ | (9,779 | ) | $ | (24,948 | ) | $ | (20,425 | ) | ||
| Loss per share: | ||||||||||||||
| Basic and diluted | $ | (0.32 | ) | $ | (0.27 | ) | $ | (0.64 | ) | $ | (0.57 | ) | ||
| Weighted average shares: | ||||||||||||||
| Basic and diluted | 38,749 | 36,720 | 38,749 | 36,048 | ||||||||||
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376